• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鉴定和验证肿瘤微环境相关特征，用于预测肺腺癌患者的预后和免疫治疗反应。

Identification and validation of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with lung adenocarcinoma.

机构信息

Department of Oncology, Suining Central Hospital, Suining, 629000, Sichuan, China.

Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

Sci Rep. 2023 Aug 21;13(1):13568. doi: 10.1038/s41598-023-40980-2.

DOI:10.1038/s41598-023-40980-2
PMID:37604869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10442419/
Abstract

Mounting evidence has found that tumor microenvironment (TME) plays an important role in the tumor progression of lung adenocarcinoma (LUAD). However, the roles of tumor microenvironment-related genes in immunotherapy and clinical outcomes remain unclear. In this study, 6 TME-related genes (PLK1, LDHA, FURIN, FSCN1, RAB27B, and MS4A1) were identified to construct the prognostic model. The established risk scores were able to predict outcomes at 1, 3, and 5 years with greater accuracy than previously known models. Moreover, the risk score was closely associated with immune cell infiltration and the immunoregulatory genes including T cell exhaustion markers. In conclusion, the TME risk score can function as an independent prognostic biomarker and a predictor for evaluating immunotherapy response in LUAD patients, which provides recommendations for improving patients' response to immunotherapy and promoting personalized tumor immunotherapy in the future.

摘要

越来越多的证据表明，肿瘤微环境（TME）在肺腺癌（LUAD）的肿瘤进展中起着重要作用。然而，肿瘤微环境相关基因在免疫治疗和临床结局中的作用仍不清楚。在这项研究中，鉴定了 6 个与肿瘤微环境相关的基因（PLK1、LDHA、FURIN、FSCN1、RAB27B 和 MS4A1）来构建预后模型。该模型建立的风险评分能够更准确地预测 1、3 和 5 年的预后，优于以前已知的模型。此外，风险评分与免疫细胞浸润和免疫调节基因（包括 T 细胞耗竭标志物）密切相关。总之，TME 风险评分可作为 LUAD 患者独立的预后生物标志物和免疫治疗反应的预测因子，为提高患者对免疫治疗的反应和促进未来的个体化肿瘤免疫治疗提供了建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/85cc7ba09a0d/41598_2023_40980_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/ae22355ed5fc/41598_2023_40980_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/f4b4fc68ddc3/41598_2023_40980_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/f111581c46de/41598_2023_40980_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/1368101e7c28/41598_2023_40980_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/eee72f33d816/41598_2023_40980_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/1cb5b02a0030/41598_2023_40980_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/de00bbcc938c/41598_2023_40980_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/9db0e1926e47/41598_2023_40980_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/122a9cb6d2eb/41598_2023_40980_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/85cc7ba09a0d/41598_2023_40980_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/ae22355ed5fc/41598_2023_40980_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/f4b4fc68ddc3/41598_2023_40980_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/f111581c46de/41598_2023_40980_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/1368101e7c28/41598_2023_40980_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/eee72f33d816/41598_2023_40980_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/1cb5b02a0030/41598_2023_40980_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/de00bbcc938c/41598_2023_40980_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/9db0e1926e47/41598_2023_40980_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/122a9cb6d2eb/41598_2023_40980_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3034/10442419/85cc7ba09a0d/41598_2023_40980_Fig10_HTML.jpg

相似文献

1
Identification and validation of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with lung adenocarcinoma.鉴定和验证肿瘤微环境相关特征，用于预测肺腺癌患者的预后和免疫治疗反应。
Sci Rep. 2023 Aug 21;13(1):13568. doi: 10.1038/s41598-023-40980-2.
2
Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.肺腺癌中基于五个免疫检查点基因（IL(R)）的表达signature 的临床意义和免疫图谱
Front Immunol. 2021 Aug 23;12:693062. doi: 10.3389/fimmu.2021.693062. eCollection 2021.
3
Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.多胺代谢相关基因特征的建立与验证可预测肺腺癌的预后和免疫治疗反应。
Front Immunol. 2023 Jun 2;14:1070953. doi: 10.3389/fimmu.2023.1070953. eCollection 2023.
4
Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.构建并验证 T 细胞增殖调节剂相关标志物用于预测肺腺癌患者的预后和免疫治疗反应。
Front Immunol. 2023 Apr 4;14:1171145. doi: 10.3389/fimmu.2023.1171145. eCollection 2023.
5
Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.鉴定免疫激活相关基因特征，以预测肺腺癌的预后和免疫治疗疗效。
Front Immunol. 2023 Jul 7;14:1217590. doi: 10.3389/fimmu.2023.1217590. eCollection 2023.
6
Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.鉴定与 TGF-β 信号相关的基因特征，用于预测肺腺癌的免疫治疗和靶向治疗。
World J Surg Oncol. 2022 Jun 6;20(1):183. doi: 10.1186/s12957-022-02595-1.
7
An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.一种与 ICD 相关的 DAMP 基因特征可预测肺腺癌患者的生存和免疫治疗反应。
Respir Res. 2023 May 31;24(1):142. doi: 10.1186/s12931-023-02443-0.
8
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.单细胞和批量 RNA 测序的综合分析确定了一个基于 B 细胞标记基因的特征，以预测肺腺癌的预后和免疫治疗反应。
Cancer Immunol Immunother. 2022 Oct;71(10):2341-2354. doi: 10.1007/s00262-022-03143-2. Epub 2022 Feb 13.
9
Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.全面分析免疫细胞死亡相关特征，预测肺腺癌患者的预后和免疫治疗效果。
BMC Med Genomics. 2023 Aug 8;16(1):184. doi: 10.1186/s12920-023-01604-w.
10
LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response.LATPS，一种基于肺腺癌肿瘤微环境的新型预后标志物，可更好地预测生存和免疫治疗反应。
Front Immunol. 2022 Nov 24;13:1064874. doi: 10.3389/fimmu.2022.1064874. eCollection 2022.

引用本文的文献

1
Single-Cell Transcriptomic Profiling Reveals KRAS/TP53-Driven Neutrophil Reprogramming in Luad: A Multi-Gene Prognostic Model and Therapeutic Targeting of RHOV.单细胞转录组分析揭示KRAS/TP53驱动的肺腺癌中性粒细胞重编程：多基因预后模型及RHOV的治疗靶点
Oncol Res. 2025 May 29;33(6):1383-1404. doi: 10.32604/or.2025.062584. eCollection 2025.
2
A review of enhanced biosignature immunotherapy tools for predicting lung cancer immune phenotypes using deep learning.利用深度学习预测肺癌免疫表型的增强生物标志物免疫治疗工具综述。
Discov Oncol. 2025 May 30;16(1):966. doi: 10.1007/s12672-025-02771-1.
3
The role of the tumour microenvironment in lung cancer and its therapeutic implications.

本文引用的文献

1
Lactate regulators contribute to tumor microenvironment and predict prognosis in lung adenocarcinoma.乳酸调节剂影响肺腺癌肿瘤微环境并预测预后。
Front Immunol. 2022 Nov 25;13:1024925. doi: 10.3389/fimmu.2022.1024925. eCollection 2022.
2
FSCN1 induced PTPRF-dependent tumor microenvironment inflammatory reprogramming promotes lung adenocarcinoma progression via regulating macrophagic glycolysis.FSCN1诱导的依赖PTPRF的肿瘤微环境炎症重编程通过调节巨噬细胞糖酵解促进肺腺癌进展。
Cell Oncol (Dordr). 2022 Dec;45(6):1383-1399. doi: 10.1007/s13402-022-00726-0. Epub 2022 Oct 12.
3
The kinase PLK1 promotes the development of /-mutant lung adenocarcinoma through transcriptional activation of the receptor RET.
肿瘤微环境在肺癌中的作用及其治疗意义。
Med Oncol. 2025 May 23;42(6):219. doi: 10.1007/s12032-025-02765-7.
4
Comprehensive landscape of junctional genes and their association with overall survival of patients with lung adenocarcinoma.肺腺癌交界基因的综合概况及其与患者总生存的关联
Front Mol Biosci. 2024 May 22;11:1380384. doi: 10.3389/fmolb.2024.1380384. eCollection 2024.
激酶 PLK1 通过转录激活受体 RET 促进 /- 突变型肺腺癌的发展。
Sci Signal. 2022 Oct 4;15(754):eabj4009. doi: 10.1126/scisignal.abj4009.
4
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.表皮生长因子受体突变型非小细胞肺癌与免疫治疗抵抗：肿瘤微环境的作用。
Int J Mol Sci. 2022 Jun 10;23(12):6489. doi: 10.3390/ijms23126489.
5
The Dual Role of Mesenchymal Stromal Cells and Their Extracellular Vesicles in Carcinogenesis.间充质基质细胞及其细胞外囊泡在肿瘤发生中的双重作用
Biology (Basel). 2022 May 25;11(6):813. doi: 10.3390/biology11060813.
6
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions.靶向癌症相关成纤维细胞：挑战、机遇与未来方向。
Pharmacol Ther. 2022 Dec;240:108231. doi: 10.1016/j.pharmthera.2022.108231. Epub 2022 Jun 17.
7
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.肿瘤微环境中癌症相关成纤维细胞与免疫细胞的串扰：新发现与未来展望。
Mol Cancer. 2021 Oct 11;20(1):131. doi: 10.1186/s12943-021-01428-1.
8
FURIN correlated with immune infiltration serves as a potential biomarker in SARS-CoV-2 infection-related lung adenocarcinoma.FURIN 与免疫浸润相关，可作为 SARS-CoV-2 感染相关肺腺癌的潜在生物标志物。
Clin Exp Med. 2022 Aug;22(3):371-384. doi: 10.1007/s10238-021-00760-6. Epub 2021 Sep 12.
9
B7-H3/CD276: An Emerging Cancer Immunotherapy.B7-H3/CD276：一种新兴的癌症免疫疗法。
Front Immunol. 2021 Jul 19;12:701006. doi: 10.3389/fimmu.2021.701006. eCollection 2021.
10
A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.基于肿瘤微环境开发的风险模型可预测肺腺癌患者的总生存期，并与肿瘤免疫相关。
Oncogene. 2021 Jul;40(26):4413-4424. doi: 10.1038/s41388-021-01853-y. Epub 2021 Jun 9.